These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 29254734)
41. Survival in eteplirsen-treated Duchenne Muscular Dystrophy patients: Are there benefits beyond steroids? Burnette WB Muscle Nerve; 2024 Jul; 70(1):4-5. PubMed ID: 38708792 [No Abstract] [Full Text] [Related]
42. Use of the six-minute walk test to characterize golden retriever muscular dystrophy. Acosta AR; Van Wie E; Stoughton WB; Bettis AK; Barnett HH; LaBrie NR; Balog-Alvarez CJ; Nghiem PP; Cummings KJ; Kornegay JN Neuromuscul Disord; 2016 Dec; 26(12):865-872. PubMed ID: 27818009 [TBL] [Abstract][Full Text] [Related]
43. Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies. Reinig AM; Mirzaei S; Berlau DJ Pharmacotherapy; 2017 Apr; 37(4):492-499. PubMed ID: 28152217 [TBL] [Abstract][Full Text] [Related]
44. Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression. Lennie JL; Mondick JT; Gastonguay MR J Pharmacokinet Pharmacodyn; 2020 Feb; 47(1):91-104. PubMed ID: 31960231 [TBL] [Abstract][Full Text] [Related]
45. Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) mice following co-treatment with neutralizing interleukin-6 receptor antibodies and urocortin 2. Burns DP; Rowland J; Canavan L; Murphy KH; Brannock M; O'Malley D; O'Halloran KD; Edge D Exp Physiol; 2017 Sep; 102(9):1177-1193. PubMed ID: 28665499 [TBL] [Abstract][Full Text] [Related]
46. Drug Discovery of Therapies for Duchenne Muscular Dystrophy. Blat Y; Blat S J Biomol Screen; 2015 Dec; 20(10):1189-203. PubMed ID: 25975656 [TBL] [Abstract][Full Text] [Related]
47. Restoration of Walking After Surgical Management of Equinus in a Non-ambulatory Child With Duchenne Muscular Dystrophy: A Case Presentation. Bouchard M; Vogel LF; Apkon SD PM R; 2019 Nov; 11(11):1240-1243. PubMed ID: 30859710 [No Abstract] [Full Text] [Related]
48. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy]. Takeshima Y Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856 [TBL] [Abstract][Full Text] [Related]
49. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
50. Gait deviations in Duchenne muscular dystrophy-Part 2. Statistical non-parametric mapping to analyze gait deviations in children with Duchenne muscular dystrophy. Goudriaan M; Van den Hauwe M; Simon-Martinez C; Huenaerts C; Molenaers G; Goemans N; Desloovere K Gait Posture; 2018 Jun; 63():159-164. PubMed ID: 29751322 [TBL] [Abstract][Full Text] [Related]
51. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337 [TBL] [Abstract][Full Text] [Related]
52. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy. Beekman C; Janson AA; Baghat A; van Deutekom JC; Datson NA PLoS One; 2018; 13(4):e0195850. PubMed ID: 29641567 [TBL] [Abstract][Full Text] [Related]
53. Dystrophin analysis in carriers of Duchenne and Becker muscular dystrophy. Hoogerwaard EM; Ginjaar IB; Bakker E; de Visser M Neurology; 2005 Dec; 65(12):1984-6. PubMed ID: 16380627 [TBL] [Abstract][Full Text] [Related]
54. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy. Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862 [TBL] [Abstract][Full Text] [Related]
55. Next Generation Sequencing approach to molecular diagnosis of Duchenne muscular dystrophy; identification of a novel mutation. Ebrahimzadeh-Vesal R; Teymoori A; Azimi-Nezhad M; Hosseini FS Gene; 2018 Feb; 644():1-3. PubMed ID: 29246534 [TBL] [Abstract][Full Text] [Related]
56. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy. Wein N; Alfano L; Flanigan KM Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172 [TBL] [Abstract][Full Text] [Related]
57. Year in review 2019: Neuromuscular diseases. Birnkrant DJ; Black JB Pediatr Pulmonol; 2020 Oct; 55(10):2542-2546. PubMed ID: 32691988 [TBL] [Abstract][Full Text] [Related]
58. Utility of dystrophin and utrophin staining in childhood muscular dystrophy. Sundaram C; Vydehi B; Meena K; Murthy J Indian J Pathol Microbiol; 2004 Jul; 47(3):367-9. PubMed ID: 16295426 [TBL] [Abstract][Full Text] [Related]
59. Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity. Malerba A; Boldrin L; Dickson G Nucleic Acid Ther; 2011 Aug; 21(4):293-8. PubMed ID: 21851223 [TBL] [Abstract][Full Text] [Related]
60. The case for eteplirsen: Paving the way for precision medicine. Miceli MC; Nelson SF Mol Genet Metab; 2016 Jun; 118(2):70-1. PubMed ID: 27102846 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]